Literature DB >> 17873594

Hypertonic saline solutions for treatment of intracranial hypertension.

Sabine Himmelseher1.   

Abstract

PURPOSE OF REVIEW: This review aims to provide an update on recent knowledge gained on hypertonic saline solutions for the treatment of intracranial hypertension. Explanatory approaches to the mechanisms underlying the edema-reducing effects of the solutions are outlined, practical aspects of use are presented, and trials that assessed their clinical utility are highlighted. RECENT
FINDINGS: With an established trauma system, hypertonic saline added to conventional fluid resuscitation did not improve long-term outcome in multiple injury with hypotension and brain trauma. In intensive care, hypertonic saline reduced intracranial hypertension after subarachnoid haemorrhage, brain trauma, and a variety of other brain diseases, including cerebral edema in acute liver failure.
SUMMARY: Hypertonic saline solutions have evolved as an alternative to mannitol or may be used in otherwise refractory intracranial hypertension to treat raised intracranial pressure. With high osmolar loads, the efficacy of the solution is enhanced, but no simple relationship between the saline concentration and the clinical effects of a solution is established. Caution is advised with high osmolar loads because they carry increased risks for potentially deleterious consequences of hypernatremia or may induce osmotic blood-brain barrier opening with possibly harmful extravasation of the hypertonic solution into the brain tissue.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17873594     DOI: 10.1097/ACO.0b013e3282eff9ea

Source DB:  PubMed          Journal:  Curr Opin Anaesthesiol        ISSN: 0952-7907            Impact factor:   2.706


  16 in total

Review 1.  Therapeutic hypernatremia management during continuous renal replacement therapy with elevated intracranial pressures and respiratory failure.

Authors:  Tibor Fülöp; Lajos Zsom; Rafael D Rodríguez; Jorge O Chabrier-Rosello; Mehrdad Hamrahian; Christian A Koch
Journal:  Rev Endocr Metab Disord       Date:  2019-03       Impact factor: 6.514

2.  Osmotherapy: use among neurointensivists.

Authors:  Angela N Hays; Christos Lazaridis; Ron Neyens; Joyce Nicholas; Sarah Gay; Julio A Chalela
Journal:  Neurocrit Care       Date:  2011-04       Impact factor: 3.210

3.  Role of the mTOR pathway in LPS-activated monocytes: influence of hypertonic saline.

Authors:  Valérie Schaeffer; Saman Arbabi; Iris A Garcia; Megan L Knoll; Joseph Cuschieri; Eileen M Bulger; Ronald V Maier
Journal:  J Surg Res       Date:  2010-06-09       Impact factor: 2.192

Review 4.  Management of raised intracranial pressure.

Authors:  Naveen Sankhyan; K N Vykunta Raju; Suvasini Sharma; Sheffali Gulati
Journal:  Indian J Pediatr       Date:  2010-09-07       Impact factor: 1.967

5.  Second impact syndrome.

Authors:  Tareg Bey; Brian Ostick
Journal:  West J Emerg Med       Date:  2009-02

6.  Incidence and prognosis of dysnatremias present on ICU admission.

Authors:  Georg-Christian Funk; Gregor Lindner; Wilfred Druml; Barbara Metnitz; Christoph Schwarz; Peter Bauer; Philipp G H Metnitz
Journal:  Intensive Care Med       Date:  2009-10-22       Impact factor: 17.440

Review 7.  Purinergic regulation of neutrophil chemotaxis.

Authors:  W G Junger
Journal:  Cell Mol Life Sci       Date:  2008-08       Impact factor: 9.261

8.  Single bolus 30% hypertonic saline for refractory intracranial hypertension.

Authors:  E H Major; P O'Connor; B Mullan
Journal:  Ir J Med Sci       Date:  2014-02-15       Impact factor: 1.568

Review 9.  ROC trials update on prehospital hypertonic saline resuscitation in the aftermath of the US-Canadian trials.

Authors:  Michael A Dubick; Pang Shek; Charles E Wade
Journal:  Clinics (Sao Paulo)       Date:  2013-06       Impact factor: 2.365

10.  Effects of hypertonic saline on macrophage migration inhibitory factor in traumatic conditions.

Authors:  Jung-Youn Kim; Sung-Hyuk Choi; Young-Hoon Yoon; Sung-Woo Moon; Young-Duck Cho
Journal:  Exp Ther Med       Date:  2012-06-11       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.